Abstract |
Pneumococcal conjugate vaccines (PCVs) are a potentially useful complement to existing treatment strategies in HIV-infected children, for whom pneumococcal infections are common and serious. This Review summarises available data on the burden of pneumococcal disease and the safety and efficacy of PCVs in HIV-infected children. The data demonstrate that children with HIV have significantly increased risk of pneumococcal disease compared with uninfected children; the serotypes included in currently licensed or near-licensure conjugate vaccines include most serotypes that cause invasive pneumococcal disease (IPD) in HIV-infected children and adults; PCVs provide substantial protection against IPD and clinical pneumonia when given to HIV-infected infants; and HIV-infected adults gain an indirect benefit when children in the community are vaccinated. PCV should be considered as an important intervention for improving the lives of HIV-infected children.
|
Authors | Sandra J Bliss, Katherine L O'Brien, Edward N Janoff, Mark F Cotton, Philippa Musoke, Hoosen Coovadia, Orin S Levine |
Journal | The Lancet. Infectious diseases
(Lancet Infect Dis)
Vol. 8
Issue 1
Pg. 67-80
(Jan 2008)
ISSN: 1473-3099 [Print] United States |
PMID | 17974480
(Publication Type: Journal Article, Review)
|
Chemical References |
- Pneumococcal Vaccines
- Vaccines, Conjugate
|
Topics |
- AIDS-Related Opportunistic Infections
(microbiology, prevention & control)
- Antiretroviral Therapy, Highly Active
(methods)
- Child
- HIV
- HIV Infections
(immunology, microbiology)
- Humans
- Pneumococcal Infections
(prevention & control, virology)
- Pneumococcal Vaccines
(immunology, therapeutic use)
- Streptococcus pneumoniae
(immunology)
- Vaccines, Conjugate
(immunology, therapeutic use)
|